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Familial Risks Between Urolithiasis 
and Cancer
Kari Hemminki1,2, Otto Hemminki3,4, Asta Försti1,2, Jan Sundquist2,5, Kristina Sundquist2,5 & 
Xinjun Li2
Urolithiasis (UL, urinary tract stone disease) has been reported to increase subsequent cancers in the 
urinary tract. Recently, we showed data that surveillance bias may be an important confounder in the 
reported associations. In the present approach we want to address the question of possible cancer risk 
posed by UL mechanistically. Both UL and cancer have strong genetic components and we hypothesize 
that familial association between UL and cancer may be plausible. We thus assess familial risks between 
UL and cancer, hoping to find an explanation why UL may pose a risk of cancer. UL patients were 
identified from hospital inpatient and outpatient records and they were organized in families based on 
the Multigeneration Register into which also national cancer data were linked. Standardized incidence 
ratios were calculated for cancer in the offspring generation when parents were diagnosed with UL, and 
conversely for UL when parents were diagnosed with cancer. Familial risks between UL and cancer were 
generally small and inconsistent providing no convincing support of genetic sharing between UL and 
cancer. However, bladder UL was associated weakly with prostate cancer, and ureter and bladder UL 
were associated with salivary gland cancer. Potential mechanisms for these findings are proposed.
Urolithiasis (UL, urinary tract stone disease) includes stones found in the kidney, ureter and urinary bladder. 
UL is a common disease affecting up to 15% of population and many patients have recurrent episodes1,2. Kidney 
stones (nephrolithiasis) form in the kidney and leave the body in the urine stream. Small stones may pass with-
out causing symptoms but stones measuring more than 5 mm tend to generate obstruction of the ureter causing 
severe pain. Some stones do not enter the ureter, instead they can grow to fill up the renal pelvis and cause kidney 
damage if untreated. Stones in the bladder have another etiology which usually relates to long term retention of 
urine in the bladder, typically through obstruction caused by prostate hyperplasia. Thus bladder stones are far 
more common among men than women. Bladder stones may form in the bladder but also seed on small stones 
originating from kidney with urine1,2. Reasons for UL are thought to be a combination of genetic and environ-
mental factors. Risk factors include high urine calcium levels, calcium supplements, hyperparathyroidism, gout, 
obesity, dehydration, urinary stasis and some foods and medications. Genetic causes of UL include many rare 
monogenic metabolic disorders, such as adenine phosphoribosyltransferase deficiency, cystinuria, Dent disease, 
familial hypomagnesemia and primary hyperoxaluria3.
There are a number of papers on UL patients reporting subsequent risks of various cancers.
For example, a meta-analysis evaluated the association between personal history of kidney stones and kidney 
cancer, and collected results from 7 studies which gave an overall relative risk (RR) of 1.76, higher for transitional 
cell carcinoma than for renal cell carcinoma, and for renal cell carcinoma only men were at risk4. A Taiwanese 
case-control study on bladder stone patients found an RR of 3.42 for bladder cancer5. Another case-control study 
associate prostate cancer with prior kidney and bladder stones6. However, the reports are not only limited to 
urological cancers but a study from Taiwan’s National Health Insurance Research Database reported that UL was 
associated with a high risk of many systemic cancers, for example of breast and lung cancers (RRs 1.84 and 1.82)7.
We recently completed a study reconsidering the above results of UL’s possible role in subsequent cancers8. To 
our surprise the associations were strong with practically all cancers. However, they decreased with the length of 
the follow-up time since the last UL episode but for many cancers RRs remained significant even after 10 years of 
follow-up. We could not exclude that patients with recurrent UL disease might have contributed to the elevated 
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risks after the long follow-up. We concluded that exclusion of surveillance bias is extremely difficult in conditions 
for which prior medical contacts have taken place8. As UL is a common disease it would be of high importance 
to unravel and settle the possible cancer risks because, if real, their population burden would be considerable and 
prevention would be at least in part possible. Here we decided to approach the problem through a mechanistic 
reasoning and addressing two research questions: 1) directly assessing whether UL and cancer share familiar 
links, and 2) indirectly using the results from 1) to conclude whether UL may be associated with individual 
cancer risk. As both UL and cancer have a genetic component we hypothesized that they share familial risks, i.e., 
in families with UL certain cancers should be in excess, and conversely, in families with cancer UL should be in 
excess. When UL and cancer would be assessed in different generations, surveillance bias should be non-existent 
Offspring Parents
Total population 8,468,901 7,759,522






Mean age at diagnosis 47.0 ± 14.8 54.3 ± 16.3
Median age 48 54
Incidence rate per 100 000 
person years* 84.8 78.9
Diagnosis of cancer, 1958–2012 529,923 474,686
Mean age at diagnosis 52.7 ± 15.2 69.2 ± 12.1
Median age 56 71
Incidence rate per 100 000 
person years* 442.8 387.5
Table 1. Population and case numbers for urolithiasis and cancer. *Age adjusted for the European standard 
population.
Cancer site in 
offspring
Kidney Ureter Bladder All
O SIR 95% CI O SIR 95% CI O SIR 95% CI O SIR 95% CI
Upper aerodigestive 
tract 57 0.93 0.71 1.21 71 0.84 0.65 1.06 40 0.94 0.67 1.28 195 0.95 0.82 1.09
Salivary gland 13 1.48 0.78 2.53 23 1.97 1.25 2.97 7 1.52 0.60 3.16 48 1.74 1.28 2.30
Stomach 24 0.75 0.48 1.12 51 1.15 0.85 1.51 23 0.93 0.59 1.40 111 1.01 0.83 1.22
Small intestine 24 1.90 1.21 2.82 18 1.04 0.62 1.65 13 1.47 0.78 2.52 60 1.42 1.08 1.83
Colon 172 1.15 0.98 1.33 217 1.05 0.92 1.20 107 0.99 0.81 1.20 535 1.06 0.97 1.15
Rectum 81 0.90 0.71 1.12 132 1.05 0.88 1.24 68 0.98 0.76 1.24 305 0.99 0.88 1.10
Liver 88 1.26 1.01 1.55 86 0.88 0.70 1.09 50 0.97 0.72 1.28 254 1.06 0.94 1.20
Pancreas 31 0.89 0.61 1.27 55 1.11 0.83 1.44 28 0.97 0.64 1.40 125 1.02 0.85 1.21
Lung 127 1.05 0.88 1.25 148 0.87 0.73 1.02 90 0.87 0.70 1.07 399 0.93 0.84 1.03
Breast 665 1.05 0.98 1.14 903 1.05 0.98 1.12 450 1.06 0.96 1.16 2195 1.05 1.01 1.09
Cervix 1572 1.00 0.95 1.05 1978 0.98 0.94 1.03 437 0.94 0.85 1.03 4478 0.99 0.96 1.02
Endometrium 67 0.95 0.74 1.21 84 0.89 0.71 1.11 71 1.26 0.99 1.60 240 1.00 0.88 1.13
Prostate 289 1.08 0.96 1.21 384 0.98 0.89 1.09 292 1.12 0.99 1.25 1044 1.06 0.99 1.12
Kidney 57 1.02 0.78 1.33 78 1.06 0.83 1.32 31 0.85 0.58 1.21 188 1.04 0.89 1.20
Urinary bladder 68 1.05 0.82 1.34 96 1.06 0.86 1.29 44 0.82 0.59 1.10 221 0.98 0.85 1.11
Melanoma 404 1.07 0.97 1.18 533 1.06 0.98 1.16 219 1.16 1.01 1.32 1254 1.07 1.01 1.13
Nervous system 226 1.04 0.91 1.19 318 1.14 1.02 1.27 89 1.02 0.82 1.25 692 1.07 0.99 1.15
Endocrine glands 70 0.94 0.73 1.19 99 1.01 0.82 1.23 36 0.93 0.65 1.28 218 0.94 0.82 1.07
Bone 25 1.06 0.68 1.56 30 1.02 0.69 1.46 1 0.17 0.00 0.99 69 1.05 0.81 1.32
Hodgkin disease 56 1.03 0.78 1.34 67 0.99 0.77 1.26 14 1.01 0.55 1.70 157 1.03 0.88 1.21
Leukemia 126 0.93 0.77 1.10 172 1.00 0.85 1.16 53 0.94 0.70 1.23 389 0.96 0.87 1.06
Unspecified primary 52 0.98 0.73 1.29 74 1.01 0.80 1.27 34 0.85 0.59 1.19 171 0.95 0.81 1.10
All 5013 1.02 0.99 1.05 6642 1.02 0.99 1.04 2615 1.02 0.98 1.06 15729 1.02 1.01 1.04
Table 2. SIR of cancer in offspring when parents were diagnosed with UL. Bold type: 95% CI does not include 
1.00 O = observed number of cases; SIR = standardized incidence ratio; CI = confidence interval. Column ‘All’ 
includes data for mixed stones which are not shown separately. They included 1459 cases for this table.
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or minimal. Demonstration of familial risk between UL and cancer would offer unbiased evidence and a plausible 
mechanism for individuals risks, i.e., why UL patients have an increased risk of cancer. We use the nation-wide 
Swedish Family-Cancer Database for the study.
Results
Person numbers and characteristics of the UL and cancer patients are shown in Table 1 separately for the off-
spring (8.5 million) and parental (7.8 million) generations. Respective numbers of UL patients were 130,091 and 
168,132, giving age-standardized incidence rates of 84.8 and 78.9 per 100,000. The numbers of cancer patients 
in the two generation were 529,923 and 474,686, and related incidence rates were 442.8 and 387.5 per 100,000. 
The relatively higher number of cancer patients was due to the longer follow-up period, starting from year 1958 
for cancer and from year1987 for UL (for outpatients from years 2001). The median age at diagnosis was 8 years 
higher for cancer than for UL in the offspring generation but it was 17 years higher for the parental generation.
A total of 33 different cancers were included in the analyses but we show data only for those cancers for which 
any association was significant, and for simplicity deleted data for the mixed UL type; however these data were 
included in the column for combined UL, ‘All’. In Table 2 standardized incidence ratios (SIRs) are shown for 
cancer in offspring when a parent was diagnosed with UL. The overall SIR was 1.02 (N = 15,729); note that case 
numbers were much lower than in Table 1 because only familial cases were included in Table 2 and subsequent 
Tables For 4 individual cancers SIRs were significant for all types of UL combined. The highest overall SIRs were 
observed for small intestinal cancer (1.42; 1.90 when parents had kidney stones) and salivary gland cancer (1.74; 
1.97 when parents had ureter stones). Any significant association was observed for one UL type only. The overall 
SIR for prostate cancer was increased to 1.06 (95%CI 0.99–1.12) but no individual UL subtype showed an associ-
ation (yet for bladder cancer in parents the SIR of 1.12 was of borderline significance, 95%CIs 0.99–1.25). There 
was no evidence on site specific concordance: urinary tract cancers were not increased by parental UL.
In Table 3, UL risk in offspring was assessed by parental cancer. The overall SIR was 1.04 (N = 74,361), and 
overall associations were significant with 14 parental cancers. Notably, only 4 overall associations reached an SIR 
of 1.10, these being with parental cancer in the salivary glands, endometrium, kidney and endocrine glands. We 
analyzed risks by specific endocrine glands, and the only significant SIR of 1.14 (N = 572, 1.05–1.23) for overall 
UL was with parathyroid gland tumors: among these, the only significant association of 1.25 was with ureter 
stones (N = 285, 1.11–1.40). Modest site specific concordance was observed for increased SIRs for kidney and 
ureter stones associated with kidney cancer. For bladder stones no association with bladder cancer was observed 
but the association of 1.15 with prostate cancer was significant. Overall UL associated with salivary gland cancers 
Cancer site in parents
Kidney Ureter Bladder All
O SIR 95% CI O SIR 95% CI O SIR 95% CI O SIR 95% CI
Upper aerodigestive tract 678 1.04 0.96 1.12 782 1.00 0.93 1.07 89 1.07 0.86 1.32 1759 1.02 0.97 1.07
Salivary gland 93 1.28 1.03 1.57 110 1.25 1.03 1.50 17 1.75 1.02 2.81 249 1.28 1.13 1.45
Stomach 932 0.97 0.91 1.03 1206 1.01 0.95 1.06 176 1.16 1.00 1.35 2649 1.01 0.97 1.05
Small intestine 125 0.99 0.82 1.18 176 1.15 0.99 1.34 15 0.94 0.53 1.56 353 1.05 0.95 1.17
Colon 2220 1.07 1.02 1.11 2745 1.09 1.05 1.13 303 1.13 1.01 1.27 5983 1.08 1.06 1.11
Rectum 1330 1.03 0.98 1.09 1672 1.07 1.02 1.13 177 1.07 0.92 1.24 3580 1.05 1.01 1.08
Liver 659 1.02 0.94 1.10 866 1.09 1.02 1.17 77 0.84 0.66 1.05 1811 1.04 1.00 1.09
Pancreas 686 1.06 0.98 1.14 803 1.01 0.94 1.09 105 1.16 0.95 1.40 1821 1.05 1.00 1.10
Lung 1949 1.07 1.02 1.12 2230 1.02 0.98 1.07 218 0.98 0.85 1.11 5006 1.04 1.01 1.07
Breast 3253 0.98 0.95 1.01 4053 1.03 1.00 1.06 377 0.96 0.87 1.06 8771 1.01 0.99 1.03
Cervix 3023 1.05 1.01 1.08 3256 1.02 0.98 1.05 313 1.14 1.02 1.27 7611 1.04 1.02 1.06
Endometrium 654 1.16 1.07 1.25 759 1.10 1.02 1.18 81 1.10 0.88 1.37 1686 1.12 1.06 1.17
Prostate 3300 0.99 0.96 1.02 4144 1.03 1.00 1.06 478 1.15 1.05 1.25 8999 1.02 1.00 1.04
Kidney 736 1.13 1.05 1.21 886 1.11 1.04 1.19 96 1.11 0.90 1.35 1970 1.13 1.08 1.18
Urinary bladder 1072 1.04 0.98 1.10 1326 1.07 1.01 1.13 137 1.05 0.88 1.24 2882 1.06 1.02 1.10
Melanoma 996 0.96 0.90 1.02 1221 1.02 0.96 1.08 111 1.06 0.87 1.27 2643 0.98 0.95 1.02
Nervous system 659 1.12 1.03 1.21 713 1.04 0.96 1.12 87 1.28 1.03 1.58 1674 1.09 1.04 1.14
Endocrine glands 327 1.08 0.96 1.20 425 1.18 1.07 1.30 33 0.92 0.63 1.30 889 1.11 1.04 1.19
Bone 40 0.99 0.71 1.35 50 1.07 0.79 1.40 10 2.19 1.04 4.05 118 1.12 0.93 1.35
Hodgkin disease 93 0.99 0.80 1.21 127 1.18 0.98 1.40 20 1.82 1.11 2.81 269 1.10 0.98 1.24
Leukemia 586 1.10 1.01 1.19 685 1.08 1.00 1.16 78 1.16 0.92 1.45 1533 1.09 1.03 1.14
Unspecified primary 581 1.11 1.02 1.21 625 0.98 0.91 1.06 70 1.00 0.78 1.26 1438 1.03 0.98 1.09
All 28031 1.03 1.02 1.04 33751 1.04 1.03 1.05 3548 1.07 1.03 1.10 74361 1.04 1.03 1.05
Table 3. SIR of UL in offspring when parents were diagnosed with cancer. O = observed number of cases; 
SIR = standardized incidence ratio; CI = confidence interval. Column ‘All’ includes data for mixed stones which 
are not shown separately. They included 9031 cases for this table. Bold type: 95% CI does not include 1.00.
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in Table 2 and Table 3. The highest individual associations were found for bladder stones: bone 2.19, Hodgkin 
lymphoma 1.82 and salivary glands 1.75.
Table 4 shows risks of cancer in parents when offspring were diagnosed with UL. The analysis reversed off-
spring and parents as cases and probands from Table 2 and showed 5 times more cases. In agreement with Table 2, 
SIRs were increased for salivary gland and prostate cancers, and also for liver cancer, however the associated UL 
sites were different from Table 2.
In Table 5 gives SIRs for parental UL when offspring were diagnosed with cancers, thus reversing parents and 
offspring from Table 3; total case numbers decreased to 14,418. The two Tables shared overall increased associ-
ation between UL and salivary gland and prostate cancers, and even the types of UL (ureter for salivary gland 
cancer and bladder for prostate cancer) were shared. Shared overall associations in Tables 5 and 3 were observed 
also for colon, cervical and nervous system cancers.
Discussion
Our goal was to investigate the possible familial association of UL and cancer8. If such an association could be 
demonstrated it would offer one possible mechanism for a personal history of UL being a risk factor for cancer. 
The demonstration of the association would require that positive results should be found in complementary 
two-way analyses, shown in Tables 2 to 5. Positive two-way results were found for salivary gland, liver and pros-
tate cancers with UL. It is admitted that case numbers were very different in these Tables because parental cancer 
data spanned many more years than parental UL data. Early-onset cancers were relatively more presented in 
Table 2 compared to late-onset cancers. However, case numbers with 15,729 total cancers were quite large even in 
Table 2. Even in Table 3 with large case numbers only a few significant associations exceeded 1.10. However, for 
kidney cancer there were weak but concordant associations at anatomic sites with kidney, ureter and mixed UL in 
Table 3, which may signal biological plausibility. In order to confirm that associations were not only due to the dis-
parate follow-up times additional comparisons between offspring and parents were carried out (Tables 4 and 5). 
These essentially replicated the results for salivary gland and prostate cancers, and gave some further support to 
the possible association of kidney cancer with mixed UL. In addition to disparate follow-up times, other limita-
tions of the study were lacking information on the types of stones and on comorbidities. The results were largely 
negative and, with the exception of salivary gland, liver and prostate cancers, no familial associations were found 
with UL and cancer, even when considering site specific cancers in the urinary tract. Thus the overall conclusion 
was that there was no overall familial association between UL and cancer.
The present incidence of UL was about 80/100,000 in the parental and offspring generations. Surprisingly, 
incidence rates of UL are rarely reported in the global literature even in studies which refer to incidence in the 
Cancer site in parents
Kidney Ureter Bladder All
O SIR 95% CI O SIR 95% CI O SIR 95% CI O SIR 95% CI
Upper aerodigestive tract 331 1.10 0.99 1.23 336 0.99 0.89 1.10 29 1.10 0.74 1.58 802 1.06 0.99 1.13
Salivary gland 36 1.29 0.91 1.79 37 1.17 0.82 1.61 5 1.98 0.63 4.66 91 1.29 1.04 1.58
Stomach 441 1.08 0.98 1.19 500 1.04 0.95 1.13 62 1.42 1.09 1.82 1163 1.10 1.04 1.16
Small intestine 79 1.13 0.90 1.41 83 1.04 0.83 1.29 7 1.08 0.43 2.24 182 1.02 0.88 1.18
Colon 1435 1.08 1.02 1.13 1683 1.09 1.04 1.14 141 1.09 0.92 1.29 3699 1.08 1.05 1.12
Rectum 800 1.04 0.97 1.12 941 1.06 0.99 1.13 80 1.10 0.87 1.37 2049 1.04 1.00 1.09
Liver 412 1.08 0.98 1.19 502 1.13 1.03 1.23 32 0.81 0.55 1.14 1067 1.09 1.02 1.15
Pancreas 407 1.08 0.98 1.19 448 1.03 0.93 1.13 44 1.18 0.86 1.59 1018 1.06 0.99 1.12
Lung 1291 1.14 1.08 1.20 1442 1.11 1.05 1.17 102 1.03 0.84 1.25 3233 1.12 1.08 1.16
Breast 1951 0.93 0.89 0.97 2298 0.98 0.94 1.02 159 0.90 0.76 1.05 5060 0.96 0.93 0.98
Cervix 609 1.12 1.03 1.21 555 1.06 0.98 1.15 44 1.15 0.84 1.55 1416 1.11 1.05 1.16
Endometrium 548 1.09 1.00 1.18 609 1.05 0.97 1.14 45 1.01 0.74 1.35 1376 1.07 1.02 1.13
Prostate 2763 1.01 0.97 1.05 3265 1.04 1.01 1.08 266 1.10 0.97 1.24 7164 1.03 1.00 1.05
Kidney 408 1.13 1.02 1.24 490 1.18 1.08 1.29 42 1.25 0.90 1.69 1074 1.16 1.10 1.24
Urinary bladder 810 1.06 0.98 1.13 915 1.03 0.97 1.10 67 0.94 0.73 1.19 2052 1.05 1.00 1.09
Melanoma 634 0.91 0.84 0.98 745 0.97 0.90 1.04 56 1.00 0.76 1.30 1632 0.93 0.89 0.98
Nervous system 393 1.17 1.05 1.29 400 1.08 0.98 1.19 36 1.33 0.93 1.84 947 1.13 1.06 1.20
Endocrine glands 237 1.03 0.90 1.17 279 1.08 0.96 1.22 22 1.09 0.68 1.65 606 1.04 0.96 1.13
Bone 15 1.02 0.57 1.68 17 1.05 0.61 1.69 1 0.82 0.00 4.70 40 1.09 0.78 1.48
Hodgkin disease 36 1.16 0.81 1.61 55 1.62 1.22 2.11 2 0.74 0.07 2.73 105 1.36 1.11 1.64
Leukemia 498 1.04 0.95 1.14 565 1.03 0.94 1.12 54 1.19 0.89 1.55 1265 1.04 0.98 1.09
Unspecified primary 614 1.14 1.06 1.24 692 1.10 1.02 1.19 63 1.16 0.89 1.49 1544 1.12 1.06 1.17
All 18181 1.04 1.02 1.05 20846 1.04 1.03 1.06 1701 1.06 1.01 1.12 46413 1.04 1.03 1.05
Table 4. SIR of cancer in parents when offspring were diagnosed with UL. Bold type: 95% CI does not include 
1.00. O = observed number of cases; SIR = standardized incidence ratio; CI = confidence interval Column ‘All’ 
includes data for mixed stones which are not shown separately. They included 5685 cases for this table.
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title; if at all, these may give incidence in a defined subpopulation. However, population based incidence rates for 
renal stones (including kidney and ureter) were 100.1/100,000 in Rochester, US in year 20009. The present inci-
dence rates for cancer (400/100,000) were at the level of the Swedish rates in the 1990s10.
The associations of UL with prostate cancer were not strong but they were most consistent with bladder UL. 
The reason could be shared familial risk but there is an alternative explanation. Prostate cancer has a large familial 
component whereby fathers and sons may both have prostate cancer11. Prostate hyperplasia is a risk factor for 
diagnosis of prostate cancer, and is also known to be familial; it is thus likely that both fathers and sons suffer from 
this condition12,13. The alternative explanation would then be familial tendency for bladder outlet obstruction and 
the resulting urine retention as a course of bladder stones.
The most consistent familial associations between cancer and UL were found with salivary gland cancers and 
ureter stones, but also with kidney and bladder stones. Salivary glands and particularly the submandibular gland 
may harbor stones in their ductal systems, referred to as sialolithiasis14. X-ray microanalysis has shown that sialo-
liths and kidney stones have largely similar elemental composition of calcium, phosphorous, magnesium, sodium, 
chloride, silicon, iron, and potassium14. A further clue to the puzzle is a case-control study on close to 1000 sialo-
lithiasis patients identified from the Taiwan Longitudinal Health Insurance Database15. A significant difference 
in the prevalence of prior nephrolithiasis was found between cases and controls (10.25% vs 2.28%, p < 0.001) 
with a relative risk of 4.7415. We searched literature and consulted an expert on the possible relationship between 
sialolithiasis and salivary gland cancer but found no relevant data. Hypothetically, if sialolithiasis were related to 
salivary gland cancer the present results would make sense as sialolithiasis and UL are associated with each other. 
Thus the present link between UL and salivary gland cancer would be explained by sialolithiasis associating with 
salivary gland cancer.
The association of parathyroid tumors with ureter stones may point to a mechanistic basis because parathyroid 
tumors are usually diagnosed because of hypercalcemia and hypercalciuria and these conditions are important 
risk factors for UL1,16. However the risk was modest and the SIR reached statistical significance only in Table 3.
In conclusion, the present study did not provide data in support of UL leading to systemic cancers. Nor did 
we find any strong support for the induction of local tumors in the urinary tract; however, as the cause for local 
tumors may be chronic mechanical wear and inflammation, a family study may not find such a link4,5,7. We found 
support for a weak familial association of bladder UL and prostate cancer but could not distinguish between 
genetic or familial prostate hyperplasia mechanisms. Unexpected findings showed associations of ureter and 
bladder UL with salivary gland cancers. The likely initial link was familial predisposition to both salivary gland 
and urinary tract stones but the necessary final link between salivary gland stones and salivary gland cancer needs 
yet to be demonstrated.
Cancer site in 
offspring
Kidney Ureter Bladder All
O SIR 95% CI O SIR 95% CI O SIR 95% CI O SIR 95% CI
Upper aerodigestive 
tract 58 0.93 0.71 1.21 73 0.86 0.68 1.09 41 1.05 0.75 1.42 198 0.98 0.84 1.12
Salivary gland 14 1.55 0.85 2.61 23 1.90 1.20 2.86 6 1.34 0.48 2.95 48 1.70 1.26 2.26
Stomach 29 0.93 0.62 1.34 55 1.28 0.97 1.67 21 0.97 0.60 1.48 117 1.12 0.93 1.34
Small intestine 25 1.90 1.23 2.81 18 1.00 0.59 1.58 15 1.75 0.97 2.89 64 1.47 1.13 1.88
Colon 172 1.15 0.99 1.34 223 1.10 0.96 1.25 106 1.09 0.89 1.32 539 1.10 1.01 1.20
Rectum 90 0.92 0.74 1.13 145 1.08 0.91 1.27 66 0.96 0.74 1.22 326 0.99 0.89 1.11
Liver 45 1.33 0.97 1.78 41 0.90 0.65 1.23 26 1.18 0.77 1.74 123 1.11 0.93 1.33
Pancreas 29 0.84 0.56 1.20 52 1.09 0.81 1.43 26 1.03 0.67 1.50 118 1.01 0.83 1.21
Lung 121 1.10 0.91 1.31 137 0.91 0.76 1.07 87 1.08 0.87 1.33 377 1.01 0.91 1.12
Breast 608 1.05 0.97 1.14 856 1.08 1.01 1.15 423 1.12 1.02 1.23 2060 1.08 1.03 1.13
Cervix 1443 1.04 0.99 1.10 1830 1.04 0.99 1.09 381 0.98 0.88 1.08 4122 1.05 1.02 1.08
Endometrium 61 1.10 0.84 1.42 72 0.94 0.74 1.19 58 1.40 1.06 1.80 202 1.07 0.93 1.23
Prostate 260 1.06 0.94 1.20 361 1.05 0.95 1.17 260 1.27 1.12 1.44 948 1.10 1.04 1.18
Kidney 55 1.03 0.77 1.34 82 1.16 0.92 1.44 33 1.04 0.71 1.46 194 1.13 0.98 1.30
Urinary bladder 68 1.10 0.85 1.39 102 1.20 0.98 1.46 41 0.91 0.65 1.24 225 1.08 0.94 1.23
Melanoma 384 1.08 0.98 1.20 520 1.10 1.01 1.20 193 1.11 0.96 1.28 1195 1.09 1.02 1.15
Nervous system 211 1.11 0.97 1.27 278 1.14 1.01 1.28 65 0.88 0.68 1.13 608 1.08 1.00 1.17
Endocrine glands 67 0.98 0.76 1.25 106 1.18 0.96 1.42 36 1.07 0.75 1.48 222 1.05 0.92 1.20
Bone 21 1.00 0.62 1.53 34 1.28 0.89 1.79 1 0.19 0.00 1.11 70 1.18 0.92 1.50
Hodgkin disease 50 1.05 0.78 1.38 61 1.02 0.78 1.32 12 1.01 0.52 1.77 143 1.07 0.90 1.26
Leukemia 116 0.99 0.82 1.19 158 1.08 0.92 1.26 46 1.08 0.79 1.44 354 1.04 0.94 1.16
Unspecified primary 46 1.07 0.79 1.43 62 1.06 0.81 1.36 28 0.99 0.65 1.43 145 1.02 0.86 1.21
All 4589 1.05 1.02 1.08 6141 1.07 1.04 1.09 2330 1.09 1.05 1.14 14418 1.07 1.05 1.09
Table 5. SIR for UL in parents when offspring were diagnosed with cancer. Bold type: 95% CI does not include 
1.00. O = observed number of cases; SIR = standardized incidence ratio; CI = confidence interval Column ‘All’ 
includes data for mixed stones which are not shown separately. They included 1358 cases for this table.
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Patients and Methods
Family relationships were obtained from the Multigeneration Register, containing the Swedish population in fam-
ilies and spanning more than a century. ‘The offspring generation’ was born after 1931 and ‘the parental genera-
tion’ was born any time earlier. By the last year of the study, 2012, the offspring generation reached age 80 years. 
The offspring generation with information of both parents totaled 8.5 million index individuals. UL patients 
were identified using the nationwide Swedish Hospital Discharge Register (1987–2012) and the Outpatient 
Register (2001–2012). The first UL diagnosis in either register was included and a patient was only entered once. 
Information from the registers was linked at the individual level via the national 10-digit civic registration num-
ber to the Swedish national Cancer Registry. Both invasive and in situ cancers were included; however in situ cases 
contributed essentially only to cervical cancer. In the linked dataset, civic registration numbers were replaced 
with serial numbers to ensure the anonymity. Revisions 9 (1987–1996) and 10 (1997-) of the International 
Classification of Diseases (ICD) was used to identify UL diagnostic codes. Only 54,500 patients were diagnosed 
during the ICD-9 period, compared to 166,600 in the ICD-10 period. The total number of patients diagnosed 
with UL during years 1987 to 2012 was 211,718, distributed by the most common type, ureter stones (91,397), 
followed by kidney stones (77,972), mixed stones (23,890) and bladder stones (18,459). For mixed stones the 
location between kidney and ureter was undefined or stones were present in both.
Standardized incidence ratios (SIRs) were calculated for the offspring generation as the ratio of observed to 
expected number of cases. SIRs were calculated for cancer in offspring whose parents were diagnosed with UL, or 
conversely, for UL in offspring whose parents were diagnosed with cancer. The follow-up for cancer was started 
from January 1st 1958, date of birth or date of immigration whichever came last, and continued until diagnosis 
of cancer, death, emigration, or the end of the study (December 31st, 2012) whichever came first. Follow-up for 
UL was started from 1987 and ended at diagnosis of UL, death or end of follow-up, 2012. The expected numbers 
were calculated for all individuals without a family history of UL or of cancer (essentially the whole Swedish 
population), and the rates were standardized by 5-year-age, gender, period (5 years group), socioeconomic status 
(farmers, self-employed, professionals, white collar workers, blue collar workers, others) and residential area 
(large cities, southern Sweden, northern Sweden). The 95% confidence interval (95%CI) of the SIR was calculated 
assuming a Poisson distribution. The SAS software version 9.3 was used for the statistical analyses.
The study was approved by the Regional Ethical Review Board of Lund University (no. 2012/795). The ethical 
permission waived informed consent because anonymous health records were used. The study was conducted 
following relevant regulations.
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